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is a malignant neoplasm of immature T-cells. Immunophenotypic subtypes of T-ALL/LBL that correspond to T-cell maturation stages have been recognized. [1] [2] [3] [4] Recently, a subtype of T-ALL/LBL derived from thymic cells at the early T-cell precursor (ETP) differentiation stage has been recognized. 5, 6 Early T-cell precursors are recent immigrants from the bone marrow to the thymus, derived from hematopoietic stem cells, which retain a certain level of multilineage pluripotency. 7, 8 By gene expression profiling (GEP), ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells. 5 The definition of ETP-ALL/LBL is based on the immunophenotype of the leukemic cells, which are typically CD1a(-), CD8(-), CD5(-/dim), and positive for one or more stem cell or myeloid antigens. 5 In the WHO classification, ETP-ALL/LBL falls within the 'early'
T-ALL/LBL category. ETP ALL has been reported in 11-12% of childhood T-ALL/LBL 5, 9 , and in 7.4% of adult T-ALL/LBL 9 . ETP-ALL/LBL is also characterized by a distinct molecular profile with a lower incidence of NOTCH1 mutations and frequent presence of FLT3 and DNMT3A mutations. 6, [10] [11] [12] Importantly, ETP-ALL/LBL is associated with a significantly worse outcome in children and young adults compared to other T-ALL/LBL subtypes. 5, 13 For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Page 6 of 31 Combination chemotherapy has been the cornerstone of T-ALL/LBL treatment.
Yet, despite an overall complete response (CR) rate of 90-95%, approximately one-third of patients experience disease relapse, and the 5-year overall survival (OS) rate for adults is around 50-55%.
14-17 These outcomes highlight the need for alternate therapeutic approaches, ideally based on a prognostication strategy that identifies T-ALL/LBL patients at a high risk for relapse.
The aim of this study is to characterize the clinical features of patients with ETP-ALL/LBL seen at our institution and treated on frontline regimens for T-ALL/LBL, and to compare their outcomes to those with other T-ALL/LBL subtypes.
METHODS

Study Group
Patients with newly-diagnosed T-ALL/LBL who received frontline chemotherapy between the years 2000 and 2014 at The University of Texas MD Anderson
Cancer Center (MDACC) were identified. All patients fulfilled diagnostic criteria of T-ALL/LBL according to the WHO classification. 4 The diagnosis of T-ALL/LBL was based on the identification of a neoplastic proliferation of small to mediumsized blasts in an extramedullary mass, peripheral blood (PB) and/or bone marrow (BM). A cutoff of <20% BM blasts was used to define lymphoblastic lymphoma (LBL Table 1 ). 4 The ETP-ALL/LBL immunophenotype was defined as follows: (1) 18 . Briefly, MRD analysis was performed using a panel of markers that included in most cases CD1a, CD2, CD3 (surface and cytoplasmic), CD4, CD5, CD7, CD8, CD10, CD13, CD33, CD34, CD45, CD56, HLA-DR, and
TdT assessed on 200,000 aspirated nucleated BM cells.
Patients received frontline treatment with the following chemotherapy regimens:
hyper-CVAD alone (n=43), hyper-CVAD + nelarabine (n=44) or augmented BFM regimen (n=24). The details of these chemotherapy regimens were published previously. 17, 19, 20 Decision between the 3 regimens was based on a variety of 
Statistical analysis
Fisher's exact test and Mann-Whitney U test were used to assess categorical and continuous variables, respectively. The Spearman rank method was used to asses correlations. The Kaplan-Meier method was used to asses OS and eventfree survival (EFS) using the log-rank (Mantel-Cox) test. The former was When grouped by WHO criteria based on CD1a and sCD3 status, the most common T-ALL/LBL subtype was thymic (43%), followed by early (includes ETP-ALL/LBL) (40%) and mature (17%) (demographic details in Table 1 ). Patients with thymic subtype were more likely to present with LBL. There was no difference in the achievement of CR/CRp among patients with early, thymic or mature T-ALL/LBL subtypes (82%, 94%, and 89%, respectively, p=0.2). There was no difference in EFS (Figure 2A Table 3 . Patients with ETP presenting as ALL (n=15) had significantly worse OS compared to non-ETP patients with ALL presentation (n=61) (Figure 5, p=0.037 ). There was no difference in EFS (supplemental Figure   5 p=0.337). For patients presenting as LBL, there was no difference in outcomes of ETP (n=4) vs. non-ETP (n=31), likely due to small numbers (supplemental Figures 6 and 7 ). Three patients with ETP-ALL/LBL underwent allo-SCT in first remission (one patient is in ongoing CR for 6+ years; one patient relapsed after 3 years, and has achieved CR2 with plans for second allo-SCT; one patient relapsed after 1 year, and is receiving salvage therapy).
The prognostic significance of ETP-ALL/LBL was maintained when only hyper-CVAD based chemotherapy regimens were considered (supplemental Figure 8) .
As it was difficult to assess for MRD in patients presenting with LBL due to lack of remission tumor biopsy, MRD analysis was restricted to patients presenting with ALL. A total of 54 patients who presented with ALL had MRD data available at the time of remission. There was no difference in the MRD rate in patients with ETP-ALL (7/10 [70%]) vs. non-ETP-ALL (27/44 [61%], p=0.61). MRD negativity didn't influence the outcomes for patients with ETP-ALL; however, the patient numbers were small. By univariate analysis, the following variables were A subset of patients with early T-ALL/LBL had an immunophenotype that resembled that of ETP-ALL/LBL except for having ≥ 75% CD5 expression (ETP+CD5). 9 The OS of patients with ETP+CD5 (n=19) was similar to that of non-ETP-ALL/LBL patients and differed from that of ETP-ALL/LBL patients (p=0.059) (supplemental Figure 9 ).
DISCUSSION
We report here one of the largest series of newly-diagnosed adult patients with ETP-ALL/LBL with long-term clinical outcomes. All patients received induction chemotherapy at our institution with either hyper-CVAD chemotherapy or augmented BFM chemotherapy. 17, 19, 20 Our findings show (1) significantly poorer long-term outcomes for ETP-ALL/LBL patients compared to non-ETP-ALL/LBL patients; (2) lack of the prognostic significance of the WHO-defined immunophenotypic T-ALL/LBL categories; and, (3) favorable long-term outcomes of mature T-ALL/LBL without allo-SCT. 16 In their series, thymic was the most common subtype (56%), followed by early (23%), and mature (21%). 16 In the GIMEMA ALL study reported by Vitale et al.
21
, early T-ALL/LBL was the most common subtype (51%), followed by thymic (39%), and mature (10%). In the present study, thymic (43%) is the most common T-ALL/LBL subtype, followed by early (40%), and mature (17%). The prognostic impact of this immunophenotypic classification has been limited.
Marks et al reported outcomes of 356 adult patients with T-ALL treated on the
UKALLXII/ECOG 2993 study. 15 With the exception of CD1a expression, which was associated with a more favorable 5-year OS (64% vs. 39%; p = 0.01), none of the other WHO-defined immunophenotypic categories affected clinical outcomes. They also noted that expression of myeloid markers such as CD13
was associated with a worse 5-year OS (35% vs. 61%; p < 0.001). In retrospect, it could be postulated that these findings reflect the impact of admixed ETP-ALL/LBL cases. In the present report of newly-diagnosed patients with T-ALL/LBL, we were unable to confirm the prognostic significance of any of the WHO-defined T-ALL/LBL subtypes.
The GMALL group has reported a beneficial effect of allo-SCT for patients with early and mature T immunophenotype. 14, 16 The beneficial effect of the transplant 
